KINDSTAR GLOBAL

9960
0.8952.29% ( +0.020 )
Delay Closed: Nov 16, 16:08:11

Overview

KINDSTAR GLOBAL (9960)

Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People’s Republic of China and Mainland China. It...

Open
0.895
High
0.895
Low
0.860
Prev. Close
0.875
Volume
229.00K
Turnover
201.95K
Avg Price
0.882
Bid/Ask Ratio
-77.78%
Amplitude
4.00%
52wk High
1.205
Volume Ratio
0.53
Turnover Ratio
0.02%
52wk Low
0.855
HK Mkt Cap
923.09M
Market CapHKD
923.09M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.0464
EPSDynamic
-0.0421
EPSStatic
--
BVPS
2.88
P/B
0.31
HK Shares
1.03B
Dividend YieldTTM
10.64%
DividendTTM
0.095
Shares
1.03B
Min lot size
500
Currency
HKD

KINDSTAR GLOBAL Analyst Rating

View more

Forecast & Rating

Oct 7, 2024
Price forecast
HK$3.15252.35%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Kindstar Global (9960.HK) closed up 2.3% at HK$0.895, with the stock having touched a 52-week low of HK$0.855 this week; an afternoon dip to HK$0.860 drew bids and the shares were pulled back to the session high by the close in a V-shaped recovery on just 220,000 shares and HK$193,890 of turnover, a 0.02% turnover rate. The session coincided with a run of HKEX next-day disclosure returns on share buybacks, one at an average price of about HK$0.94. Q2 2026 revenue rose 9.26% y/y to HK$273.5m and the net loss narrowed 44.88% to HK$10.9m, yet EPS stays at -HK$0.0109 with PE of -19.3 and PB of 0.31. The price is back above MA20 of 0.892 but still under MA60 of 0.919, down 23.5% year to date and 32.2% below the HK$1.32 52-week high, with the death cross intact. Though the bounce rests on very thin turnover.

  2. Oct, 27

    Kindstar Globalgene (9960.HK) fell about 3.9% to HK$0.865, printing a fresh 52-week low of HK$0.855 at 10:14 BJ on 136,000 shares traded. Buybacks have been near-daily through October, including 5,000 shares for HK$4,502.5 on Oct 26, yet against a market capitalisation of roughly HK$892 million the support has been limited. Q2 2026 revenue rose 9.26% year on year to HK$273.5 million while the net loss narrowed 44.88% to HK$10.89 million, leaving the net margin at -3.98% and price-to-book near 0.30. The shares are down 26.07% year to date, 38.65% below the 52-week high of HK$1.41, and trade under both the MA20 of 0.912 and the MA60 of 0.933. Though the roughly 45% narrowing in losses and two consecutive quarters of about 9% revenue growth remain the counterpoint to the weak price action.

  3. Oct, 14

    Kindstar Globalgene (9960.HK) reversed early gains and drifted lower, opening flat at HK$0.935 and closing at HK$0.900, down 3.74%, after touching HK$0.895 intraday on thin volume of 781,500 shares worth about HK$0.71m. The close sits below MA20 of HK$0.923 and MA60 of HK$0.941, with the stock down 23.08% year-to-date and 42.31% below its 52-week high of HK$1.56, while the HK$0.895 low matched the prior session's 52-week trough. The latest quarter shows narrowing losses rather than growth: Q2 2026 revenue rose 9.26% year-on-year to HK$273.5m, the net loss of HK$10.9m contracted 44.88% and EPS of -HK$0.0109 improved 47.25%, leaving net margin at -3.98%. Near-daily buybacks since mid-September, including 18,000 shares for HK$16,700 on 13 October and 24,000 shares on 8 October, failed to hold intraday prices, though turnover of just 0.08% suggests sparse trading magnified the decline.

  4. Sep, 3

    Kindstar Globalgene traded flat at HK$1.00 during the morning session, recovering from an intraday low of HK$0.980, with a daily range of about 2%. The stock was supported by the company's ongoing share buyback and cancellation activities, as evidenced by multiple recent HKEX filings, coupled with the FY26 H1 results released last night showing a 44.7% narrowing of net loss to RMB 18.1 million, while revenue grew 3.7% to RMB 473.6 million. The current price is 35.9% below the 52-week high of HK$1.56 but has reclaimed both the 20-day MA (HK$0.956) and 60-day MA (HK$0.965), though the year-to-date decline stands at 14.53%. However, the company remains loss-making with a P/E of -21.59x and a P/B of 0.35x, warranting caution on the sustainability of the turnaround.

  5. Sep, 1

    Kindstar Global closed at HKD 0.995, flat from the previous close, after a session that saw prices dip to HKD 0.970 in the morning before recovering in the afternoon. Frequent share buybacks (e.g., at HKD 0.94-0.99 for cancellation) provided support, while the interim net loss narrowed 44.7% to RMB 18.1 million with revenue up 3.7% to RMB 473.6 million, driven by oncology testing. Despite the improvement, the net profit margin remained negative. The stock trades 41.5% below its 52-week high of HKD 1.71 and below both the MA20 (HKD 0.951) and MA60 (HKD 0.966), indicating a depressed valuation, though YTD it is down 14.5% with thin overall volume of 865,000 shares.

News